6 clinical profiles of patients in whom it is worth to consider the use of ramipril Review article
Article Sidebar
Published:
Mar 31, 2016
Keywords:
ramipril, arterial hypertension, cardiovascular risk
Main Article Content
Abstract
When deciding to start antihypertensive pharmacotherapy the most important thing is to estimate total cardiovascular risk based on the degree of hypertension, the presence of other most important risk factors, subclinical organ damage, coexistence of diabetes, cardiovascular and chronic kidney disease. The use of proper drug allows not only to obtain a stable antihypertensive effect, but also to maintain good quality of life, to correct hemodynamic and metabolic functions, and most of all – to extend the life by reducing morbidity and mortality of coronary events, heart failure and stroke. Ramipril plays a significant role in patients with coronary disease or multiple risk factors considering its outstanding cardiac- and vasoprotective properties.
Article Details
How to Cite
Barylski , M. (2016). 6 clinical profiles of patients in whom it is worth to consider the use of ramipril. Medycyna Faktow (J EBM), 9(1(30), 45-50. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2269
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. The Heart Outcome Prevention Evaluation Study Investigators: Effect of angiotensin-converting enzyme, ramipril on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-153.
2. Bosch J., Lonn E., Pogue J. et al.; HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
3. Yusuf S., Teo K.K., Pogue J. et al.; The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
4. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2015; 1(1): 1-70.
5. Kjoller-Hansen L., Steffensen R., Grande P.: The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J. Am. Coll. Cardiol. 2000; 35(4): 881-888.
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
7. Hall A.S., Murray G.D., Ball S.G. on behalf of the AIREX Study Investigators: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.
8. Wienbergen H., Schiele R., Gitt A.K. et al.; MITRA PLUS Study Group: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am. J. Cardiol. 2002; 90(10): 1045-1049.
9. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004; 141(2): 102-112.
10. Cleland J.G., Erhardt L., Murray G. et al.: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur. Heart. J. 1997; 18(1): 41-51.
11. Arnold J.M., Yusuf S., Young J. et al.; HOPE Investigators: Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107(9): 1284-1290.
12. Heart Outcomes Prevention Evaluation Study Investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
13. Ruggenenti P., Perna A., Gherardi G. et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
14. Lonn E., Yusuf S., Dzavik V. et al.; SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-925.
15. Szczepańska-Sadowska E., Cudnoch-Jędrzejewska A.: Fizjologia i patofizjologia układu renina–angiotensyna. W: Januszewicz A., Januszewicz W., Rużyłło W. (red.): Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005: 23-62.
16. Enseleit F., Lüscher T.F., Ruschitzka F.: Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. Eur. Heart J. 2003 (supl. 5): A31-A36.
2. Bosch J., Lonn E., Pogue J. et al.; HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
3. Yusuf S., Teo K.K., Pogue J. et al.; The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
4. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2015; 1(1): 1-70.
5. Kjoller-Hansen L., Steffensen R., Grande P.: The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J. Am. Coll. Cardiol. 2000; 35(4): 881-888.
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
7. Hall A.S., Murray G.D., Ball S.G. on behalf of the AIREX Study Investigators: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.
8. Wienbergen H., Schiele R., Gitt A.K. et al.; MITRA PLUS Study Group: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am. J. Cardiol. 2002; 90(10): 1045-1049.
9. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004; 141(2): 102-112.
10. Cleland J.G., Erhardt L., Murray G. et al.: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur. Heart. J. 1997; 18(1): 41-51.
11. Arnold J.M., Yusuf S., Young J. et al.; HOPE Investigators: Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107(9): 1284-1290.
12. Heart Outcomes Prevention Evaluation Study Investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
13. Ruggenenti P., Perna A., Gherardi G. et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
14. Lonn E., Yusuf S., Dzavik V. et al.; SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-925.
15. Szczepańska-Sadowska E., Cudnoch-Jędrzejewska A.: Fizjologia i patofizjologia układu renina–angiotensyna. W: Januszewicz A., Januszewicz W., Rużyłło W. (red.): Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005: 23-62.
16. Enseleit F., Lüscher T.F., Ruschitzka F.: Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. Eur. Heart J. 2003 (supl. 5): A31-A36.